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Abstract
Objectives: We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in
patients with a clinically isolated syndrome (CIS) and early relapsing-remitting multiple sclerosis (RRMS).
Methods: The MSBASIS Study, conducted by MSBase Study Group members, enrols patients seen from CIS onset,
reporting baseline demographics, cerebral magnetic resonance imaging (MRI) features and Expanded Disability Status
Scale (EDSS) scores. Follow-up visits report relapses, EDSS scores, and the start and end dates of MS-specific therapies. We
performed a multivariable survival analysis to determine factors within this dataset that predict first treatment
discontinuation.
Results: A total of 2314 CIS patients from 44 centres were followed for a median of 2.7 years, during which time 1247
commenced immunomodulatory drug (IMD) treatment. Ninety percent initiated IMD after a diagnosis of MS was confirmed,
and 10% while still in CIS status. Over 40% of these patients stopped their first IMD during the observation period. Females
were more likely to cease medication than males (HR 1.36, p = 0.003). Patients treated in Australia were twice as likely to
cease their first IMD than patients treated in Spain (HR 1.98, p = 0.001). Increasing EDSS was associated with higher rate of
IMD cessation (HR 1.21 per EDSS unit, p,0.001), and intramuscular interferon-b-1a (HR 1.38, p = 0.028) and subcutaneous
interferon-b-1a (HR 1.45, p = 0.012) had higher rates of discontinuation than glatiramer acetate, although this varied widely
in different countries. Onset cerebral MRI features, age, time to treatment initiation or relapse on treatment were not
associated with IMD cessation.
Conclusion: In this multivariable survival analysis, female sex, country of residence, EDSS change and IMD choice
independently predicted time to first IMD cessation.
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Introduction
The first attack of multiple sclerosis (MS), commonly an optic
neuritis, a transverse myelitis or a brainstem syndrome, is known
as a clinically isolated syndrome (CIS). Randomised-placebo
controlled studies of immunomodulatory drugs (IMDs) in patients
with CIS and early relapsing-remitting MS (RRMS) report a
significant decrease in relapse rate and a reduction of brain lesion
accumulation, suggesting that IMD therapy should be introduced
at an early stage of the disease [1–7].
As IMD therapies are only partially effective and are
parenterally administered, treatment persistence is a major issue.
It has been reported by one large study that only 55% of MS
patients continue their IMD for an 18-month period [8]. Other
studies have reported IMD discontinuation rates between 2% and
20% during the first 6 months and up to 67% at 1 year [9–13].
Even though IMD discontinuation is a frequent occurrence,
factors leading to treatment cessation are not well known. To our
knowledge, no previous studies were designed to prospectively
follow patients in clinical practice from disease onset to assess
factors that could predict IMD discontinuation.
This prospective cohort study aims to characterise treatment
persistence and the predictors of treatment discontinuation in CIS
and in early RRMS, specifically focussing on the first IMD
treatment initiated.
Methods
Ethics Statement
Human research ethics committee approval or waivers and
written informed consent from patients were obtained at each
participating site.
Database
The MSBase Incident Study (MSBASIS) is a world-wide,
investigator-initiated observational cohort study of patients with
CIS. The study commenced in December 2004. Data for the
current analysis was extracted on the 7th of February 2011. This
cohort study enrols patients from 44 MS treatment centres in 17
countries: Italy, Spain, Canada, Australia, The Netherlands,
Argentina, France, Turkey, Denmark, Cuba, Macedonia, The
USA, Belgium, Malta, Czech Republic, The UK and Romania.
For the present analysis, only centres with more than 10 enrolled
cases were included. The MSBASIS study is a sub-study of the
international MSBase Registry [14], a strictly observational
prospective cohort study monitoring routine clinical care of people
with MS attending outpatient clinics in MS specialist centres.
Minimum datasets of MS-related outcomes are updated at least
annually within the registry. Data of patients meeting the inclusion
criteria is collected by physicians using iMed, an electronic patient
record system, which generates anonymised data extract files that
are uploaded to the MSBase registry. Quality assurance through
online certification of Expanded Disability Status Scale (EDSS)
competency is required at each participating site.
Study Procedures
Patients were eligible for the study if their CIS was diagnosed
or confirmed by a participating neurologist and a baseline visit
was completed within 12 months of CIS onset. Patients with
primary progressive MS were excluded from this analysis.
Minimum baseline data requirements included: the date of CIS
onset and clinical presentation, a neurological evaluation
including Kurtzke Functional System (KFS) scores together with
an EDSS score, and a cerebral magnetic resonance imaging
(MRI) scan available at baseline (within 12 months of CIS onset).
The first cerebral MRI after onset of CIS was evaluated
according to the Barkhof criteria for dissemination in space
[15]. Other diagnostic test information was recorded if per-
formed, including spinal MRI lesion number and the presence of
CSF-restricted oligoclonal banding. Following this initial visit,
minimum annual follow-up was required, although all follow-up
visits were recorded. The minimum data collected at follow up
were the date of visit, KFS, EDSS, the date of onset and duration
of relapses, glucocorticoid therapy to treat relapses, and
commencement and cessation of disease-modifying drugs. Par-
ticipating investigators used iMed as their clinic management tool
and entered required study data at the time of clinic visits.
Incomplete or missing datasets were monitored and followed-up
bi-annually by the central study coordinator.
Definitions
The KFS and EDSS scores were determined according to the
Neurostatus system [16]. Baseline cerebral MRI scans were
performed with or without gadolinium contrast administration. If
performed with gadolinium administration, the presence or
Factors Predicting Treatment Discontinuation in MS
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absence of contrast-enhancing lesions was recorded. For this
analysis, the number of cerebral T2 lesions was categorised in 2
groups as 0–8 lesions or 9+ lesions. EDSS change during
treatment was defined as the EDSS difference between the
earliest and latest recorded visits within the treated observation
period.
Statistical Analysis
Sex, relapse, MRI criteria, clinic location and IMD product
were summarised using frequencies and percentages. Age, change
in EDSS and symptom duration were assessed for skew and as all
demonstrated non-normality these were described using medians
and inter-quartile ranges (IQR). Survival analysis provided
discontinuation estimates at different time points. Kaplan-Meier
estimates were used to describe the cumulative probability of first
treatment discontinuation. Cox Proportional Hazards Regression
was used to model associations between MRI criteria, change in
EDSS, IMD product and relapses with time to treatment
discontinuation, adjusted for potential confounders identified a
priori, including age at treatment commencement, symptom
duration, sex and clinic location (Table 1). Hazard proportionality
was assessed by analysis of scaled Schoenfeld residuals. In the
multivariable analysis illustrated in Table 2, due to highly
discordant IMD product discontinuation rates in different
countries, analysis of Italy as a separate location category led to
violation of hazard proportionality. We were able to resolve this
only through combining the Italian cohort with the cohort from
‘‘other’’ countries, which then permitted derivation of a valid
proportional adjusted Cox model. We derived and tested for
interaction effects between location and other predictors within the
multivariable model including DMT with no statistically signifi-
cant interactions demonstrated. All reported p values are two-
tailed and for each analysis p,0.05 was considered significant. All
analyses were performed using Stata version 11.0 (StataCorp,
College Station, Texas).
Results
Study Sample
A total of 2314 patients (70.9% female and 29.1% male) with
CIS were included in MSBASIS by their physicians and followed
for a median duration of 2.7 years (IQR 1.42, 4.69). Median age at
the onset of the disease was 31.5 (IQR 25.1, 39.0) years. The main
locations in which patients were recruited were Italy (22.7%),
Canada (15.0%), Australia (10.9%), Spain (10.5%) and The
Netherlands (10.4%). Baseline brain MRI scans were performed a
median of 68 days from CIS onset. During the follow-up period,
1271 patients (55.9%) experienced at least one relapse.
Treatment Characteristics
A total of 1247 patients received an IMD, of which 125 patients
(10%) were initially treated as CIS patients and 1094 (88%) had
converted to RRMS at the time of their first IMD commence-
ment. Two percent of patients had a secondary progressive MS at
the time of their first treatment initiation. There was a median
time of 8.4 months (IQR 4.8, 13.2 months) between the onset of
first symptoms and initial IMD start. Median EDSS at treatment
onset was 2 (IQR 1.0, 2.5). A total of 362 patients received
intramuscular (IM) interferon-beta (IFNb)-1a, 440 received
subcutaneous (SC) IFNb-1a, 251 received IFNb-1b and 194
received glatiramer acetate (GA). Two hundred and seventy three
patients treated with an IMD lived in Italy, 208 in Canada, 165 in
Australia, 164 in The Netherlands, 119 in Spain and 318 in other
countries. Cerebral MRI was performed with Gadolinium
injection in 80.5% of the patients. Baseline characteristics for
patients treated with each IMD treatment are reported in Table 1.
Investigator-reported reason for treatment discontinuation was not
a mandatory part of the dataset, but was reported in three broad
categories for 35% of the discontinuations. Adverse event/patient
choice was reported for 18.7% of cessations, disease progression
and lack of benefit for 10.5% and scheduled stops (eg pregnancy)
for 5.2%.
Table 1. Characteristics of the CIS and RRMS patients treated by IMD.
All IMD IM IFNb-1a SC IFNb-1a IFNb-1b GA
Patients (n) 1247 362 440 251 194
Age at treatment commencement (years) - median (IQR) 32.2 (26.0, 39.9) 33.2 (26.5, 39.9) 30.8 (24.8, 38.6) 32.3 (27.0, 41.7) 33.8 (28.2, 40.6)
Years between onset of symptoms and treatment start
(years) - median (IQR)
0.7 (0.4, 1.1) 0.7 (0.4, 1.1) 0.7 (0.4, 1.1) 0.7 (0.4, 1.3) 0.7 (0.4, 1.2)
Change in EDSS - median (IQR) 0 (20.5, 0.5) 0 (20.5, 0.5) 0 (21.0, 0.5) 0 (20.5, 0.5) 0 (21.0, 0)
Sex - n (%) Female 892 (71.5) 257 (71.0) 305 (69.3) 181 (72.1) 149 (76.8)
Location - n (%) Australia 165 (13.2) 35 (9.7) 41 (9.3) 57 (22.7) 32 (16.5)
Canada 208 (16.7) 67 (18.5) 71 (16.1) 37 (14.7) 33 (17.0)
Netherlands 164 13.2) 28 (7.7) 66 (15.0) 42 (16.7) 28 (14.4)
Spain 119 (9.5) 35 (9.7) 31 (7.1) 30 (12.0) 23 (11.9)
Italy 273 (21.9) 92 (25.4) 130 (30.0) 16 (6.4) 35 (18.0)
Other 318 (25.5) 105 (29.0) 101 (23.0) 69 (27.5) 43 (22.2)
At least one relapse during treatment n (%) 507 (40.7) 142 (39.2) 202 (45.9) 89 (35.5) 74 (38.1)
MRI - n (%) 9+ T2 hyperintensive lesions 422 (33.8) 118 (32.6) 134 (30.5) 98 (39.0) 72 (37.1)
At least 1 gadolinium enhancing lesion* 256 (25.5) 55 (19.9) 114 (30.7) 50 (25.3) 37 (23.3)
Gadolinium injection not done 243 (19.5) 86 (23.8) 69 (15.7) 53 (21.1) 35 (18.0)
Abbreviations: IM: intramuscular, SC: subcutaneous, IFN: interferon, GA: glatiramer acetate.
doi:10.1371/journal.pone.0038661.t001
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Predictors of Discontinuation of First IMD
Table 2 summarises the univariable and multivariable analyses
of predictors of discontinuation in the entire cohort. The overall
rate of discontinuation was 40.3% for all the IMD treatments
combined. Unadjusted Cox-regression modelling identified base-
line characteristics of female sex, age at start of treatment, country
of residence (increased rates of discontinuations in Australia and
Canada) and type of treatment (increased rates of discontinuation
with the two IFNb-1a preparations) as significantly associated with
increased rates of discontinuation. Additionally, both EDSS
increase and relapse during treatment were also associated with
increased cessation rates.
In the multivariable analysis, sex, location, change in EDSS and
IMD product identity were all independently predictive of
Figure 1. Kaplan-Meier survival estimates for treatment discontinuation by patient sex in CIS an early MS. Figure 1 demonstrates that
female sex is associated with a higher IMD discontinuation rate compared to male sex in our prospectively followed multinational, multicentre
cohort.
doi:10.1371/journal.pone.0038661.g001
Figure 2. Kaplan-Meier survival estimates for first treatment discontinuation by IMD in CIS an early MS. Figure 2 demonstrates a
greater rate of IMD discontinuation in early RRMS and CIS populations prescribed IM IFNbeta-1a and SC IFNbeta-1a as compared with IFNbeta-1b and
Glatiramer Acetate.
doi:10.1371/journal.pone.0038661.g002
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treatment discontinuation (Table 2). Females ceased immuno-
modulatory treatment at a higher rate compared to males
(Figure 1). Patients in Australia and in Canada experienced
increased rates of first IMD discontinuation compared to patients
managed in Spain. The third significant predictor of IMD
cessation was an increase in EDSS score during treatment. The
Hazard ratio of treatment cessation was 1.21 per unit increase in
EDSS score during treatment. Although predictive of increased
cessation rates on univariable analysis, occurrence of a relapse on
treatment and age at treatment commencement were not
significant in multivariable analyses, regardless of the combination
of covariates it was modelled with, and were thus excluded from
the final multivariable model.
The IMD product identity was also associated with different
discontinuation rates in the adjusted analysis (Figure 2). After
commencement of IM IFNb-1a, 44% of the patients, followed up
for a median of 3.0 years, ceased their treatment. For SC IFNb-1a,
there were 43% of discontinuations over a 2.9 year median follow-
up time. For IFNb-1b, there were 37% discontinuations over 2.8
years of median follow-up time and 31% of the patient treated
with GA stopped their treatment over a 2.3 year median follow-up
period. In the multivariable analysis, patients whose first IMD was
one of the two IFNb-1a preparations had significantly higher
discontinuation rates than those who commenced on IFNb-1b or
GA. However, IMD discontinuation rates for each product varied
greatly between different countries (see Table 3).
Baseline cerebral MRI characteristics (presence of gadolinium
enhanced lesion or number of T2 lesions) and the time between
CIS onset and treatment commencement were not associated with
time to treatment discontinuation.
Predictors of Discontinuation for Each
Immunomodulatory Treatment
In the univariable analysis of the predictors of discontinuation
for each of the four IMDs, female sex was found to be a significant
predictor of increased rate of discontinuation of IM and SC IFNb-
1a, with a strong trend for IFNb-1b (Table 3). However, female
sex was not a risk factor for discontinuation in GA-treated patients.
Whereas increasing disability was a significant predictor of
discontinuation for IM and SC IFNb-1a and GA, relapse
occurrence on treatment was a significant factor of discontinuation
only for patients treated with IM IFNb-1a. Discontinuation rates
for IMDs were greater in Canada (51.4%) and Australia (47.3%)
than in Italy (38.1%) or Spain (29.4%), with marked differences in
discontinuation hazards between IMD preparations within coun-
tries (Table 3). For instance, relative to Spain as a comparator, the
Australian patients’ discontinuation rates were much higher for
IM IFNb-1a and for GA than for SC IFNb-1a and IFNb-1b.
Age at treatment commencement and MRI features, namely
gadolinium enhancing lesion presence and T2 hyperintense lesion
load, were not associated with discontinuation rate for any of the
IMDs.
Treatment Decisions Post Discontinuation of
Immunomodulatory Treatment
Of the 503 recorded first IMD discontinuations, 9 patients did
not record a subsequent EDSS visit and a further 53 patients
recorded visits less than 12 months post-discontinuation follow-up
(as of the data extract date). Of the remaining 441 patients who
discontinued treatment, 301 (68.3%) commenced a second IMD
within 12 months of ceasing the first. Of these 301 patients, only
6.9% restarted on their original IMD. Median time to start a
Table 3. Predictors of discontinuation by immunomodulatory treatment in early MS and CIS (Univariable Cox Regression).
Predictor Level IM IFNb-1a SC IFNb-1a IFNb-1b GA
UHR (95% CI) p UHR (95% CI) p UHR (95% CI) p UHR (95% CI) p
Age at treatment commencement 2 0.98 (0.97, 1.00) 0.059 0.99 (0.97, 1.00) 0.086 1.00 (0.98, 1.02) 0.760 1.02 (1.00, 1.05) 0.105
Years between onset of symptoms
and treatment start
- 0.99 (0.84, 1.18) 0.935 0.98 (0.81, 1.18) 0.848 0.93 (0.78, 1.11) 0.410 1.07 (0.84, 1.37) 0.584
Change in EDSS - 1.23 (1.12, 1.36) ,0.001 1.26 (1.14, 1.40) ,0.001 1.01 (0.87, 1.19) 0.857 1.24 (1.03, 1.50) 0.021
Sex Female 1.45 (1.00, 2.08) 0.048 1.49 (1.07, 2.07) 0.018 1.52 (0.93, 2.47) 0.094 0.94 (0.52, 1.69) 0.842
Male 1.00 1.00 1.00 1.00
Location Australia 2.58 (1.23, 5.43) 0.013 1.42 (0.62, 3.27) 0.409 1.52 (0.77, 3.02) 0.229 2.57 (0.84, 7.92) 0.099
Canada 2.40 (1.23, 4.68) 0.010 1.51 (0.70, 3.24) 0.289 0.95 (0.45, 2.02) 0.901 1.54 (0.50, 4.79) 0.455
Netherlands 1.05 (0.46, 2.44) 0.901 1.25 (0.57, 2.76) 0.577 0.96 (0.46, 2.00) 0.908 2.92 (0.96, 8.89) 0.059
Spain 1.00 1.00 1.00 1.00
Italy 1.40 (0.72, 2.73) 0.322 1.01 (0.48, 2.13) 0.974 0.46 (0.15, 1.43) 0.180 0.83 (0.25, 2.76) 0.759
Other 1.05 (0.53, 2.06) 0.890 1.14 (0.55, 2.35) 0.719 0.53 (0.24, 1.12) 0.068 0.94 (0.29, 3.07) 0.925
At least one relapse during treatment Yes 1.61 (1.18, 2.20) 0.003 1.15 (0.86, 1.52) 0.352 1.49 (0.99, 2.24) 0.057 1.24 (0.75, 2.06) 0.407
No 1.00 1.00 1.00 1.00
MRI - T2 hyperintensive lesions ,9 1.00 1.00 1.00 1.00
9+ 1.06 (0.76, 1.49) 0.718 1.18 (0.87, 1.61) 0.287 0.85 (0.55, 1.31) 0.461 1.52 (0.89, 2.59) 0.126
MRI - Gadolinium enhancing lesion At least 1 1.16 (0.75, 1.79) 0.505 1.12 (0.81, 1.55) 0.494 1.03 (0.61, 1.75) 0.898 0.59 (0.27, 1.33) 0.203
Zero 1.00 1.00 1.00 1.00
Not done 1.13 (0.78, 1.64) 0.516 0.87 (0.57, 1.33) 0.518 0.99 (0.59, 1.66) 0.962 1.17 (0.62, 2.18) 0.631
Abbreviations: CI: Confidence Interval, UHR: Unadjusted Hazard Ratio, IM: intramuscular, SC: subcutaneous, IFN: interferon.
GA: glatiramer acetate.
doi:10.1371/journal.pone.0038661.t003
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second IMD in this group was 5 days (IQR: 0, 45). Conversely,
almost one third of patients (31.7%) did not recommence an IMD
within twelve months of first IMD cessation.
Discussion
The objective of this study was to identify factors influencing
first IMD discontinuation in early RRMS and CIS during up to 6
years of follow up. Our overall rate of discontinuation was 40.3%,
with a median study follow-up of 2.7 years. Of these patients,
31.7% remained untreated 12 months after IMD discontinuation.
Female sex, country of residence, EDSS change on treatment and
IMD choice were the most important independent factors
influencing time to first IMD discontinuation. Baseline MRI
criteria did not have a significant influence on treatment
persistence.
Although data gathered in prospective cohort studies is less
complete than that generated by clinical trials, there are also
advantages of analyses such as the one presented [17]. Firstly, as
our study is observational, it allows the characterisation of long-
term drug utilisation patterns. The creation of a pre-defined study
protocol, contemporaneous and prospective recruitment, central-
ised data monitoring and data query generation contribute to high
data accuracy. Given that only patients seen within one year of
their first reported symptom onset (median time of 4.5 months) are
included, our dataset provides much greater data accuracy than
retrospective studies, which are often confounded by recall bias.
Focussing on discontinuations of first IMD only allows us to
analyse discontinuation without the potential biases related to
previous IMD exposure. Additionally, the nature of the MSBASIS
data acquisition, in which the MSBase registry receives anon-
ymised data uploads from an electronic medical record used in
day-to-day clinical management, facilitates data accuracy and
timeliness of event reporting because no separate transcription
from medical records to online data portals or paper forms is
required. Several countries host multicentre registry studies
including Denmark, Sweden, Italy, Germany and France
[18,19]. However, MSBase is the first global online MS registry
using a contemporaneously recruited study population assessed
using the same protocol and thus allows us to compare persistence
rates in different countries.
Previous studies have reported discontinuation rates in patients
with RRMS [8–13]. In general, the discontinuation rates reported
in other studies vary widely, possibly suggesting geographic trends.
A retrospective study in British Colombia reported a 39%
discontinuation rate during a 3-year mean follow-up period for
patients treated with IFNb and a high proportion of interruption
(27%) the first 6 months [20]. In an Italian study, 46% of the
patients stopped their treatment with IFNb during a 4.2 year
mean follow-up period [10]. However, two recent US studies
found a much higher rate of discontinuation for patients treated
with GA and IFNb (45% over an 18 month period and between
40% and 67% at one year follow-up, respectively) [8,12]. Both of
these latter studies were retrospective and based on administrative
claim data from insurance companies. Interestingly, a Spanish
study reported a very low rate of IMD discontinuation (17%
stopped and 5% switched their IMD during a 47 month mean
time of follow up), very similar to data obtained in post-marketing
studies [13,21]. Our discontinuation rate of 40.3% with a median
study follow-up of 2.7 years is in the mid-range of most of the other
studies, with the exception of the Spanish study. To our
knowledge, none of the previous studies have followed patients
in clinical practice from disease onset.
The general definition of treatment adherence includes
treatment compliance and treatment persistence. Compliance
can be defined as the ability to follow a pre-specified administra-
tion schedule without missing doses, not assessed in the current
study. Treatment persistence refers to a patient’s ongoing
motivation to continue a given treatment. Discontinuation can
be initiated by the physician or the patient, or, ideally by consensus
between both. Reasons for patient-initiated and physician-initiated
discontinuation could be different. Physicians could suggest
discontinuation when they observe relapses or disability progres-
sion, whereas patients might cease an IMD unilaterally if they
suffer severe injection related side effects, needle phobia or
persistent flu-like symptoms, issues that they might be reluctant to
discuss with their treating physician [22,23]. The main reasons for
IMD discontinuation identified in the literature to date are the
ones suggested above, namely injection-related side effects,
perceived lack of efficacy and adverse events [13,20]. In an Italian
study, only 4.9% of the patients stopped their IMD treatment for
any other reason [10].
After an IMD treatment discontinuation, patients either switch
to another IMD or disease-modifying drug or disengage from
treatment. In either case, IMD discontinuation generally repre-
sents a failure of the initial prescribed therapy. Our study is the
first to systematically assess the rate of first IMD discontinuation,
among seen-from onset patients with CIS or early RRMS.
One key finding in this analysis is that, after adjusting for other
factors, female sex is associated with increased rates of discontin-
uation in early MS and CIS, consistent with prior reports
[8,13,20]. An increase of adverse effects such as flu-like symptoms
with fixed dose interferon medications related to a low body mass
index of female compared to male patients might be one
explanation, [23] as we did not observe an excess of female
discontinuations for GA. A second reason for female treatment
discontinuation might be desire of a pregnancy.
Our study confirms that increasing EDSS score is a predictor of
treatment discontinuation. This is consistent with prior registry
studies, which identified relapses and EDSS instability as
associated with treatment discontinuation [13,20].
The global nature of our cohort reveals major regional
differences. As mentioned above, different rates of discontinuation
were reported in prior studies with higher rates in the United
States and Canada compared with Spain [10,13,20]. As these
studies were methodologically heterogeneous, they are difficult to
compare. Our study clearly shows that persistence rates in study
centres in Spain and Italy were much higher than in Australian or
Canadian centres. This may relate to differences in patient
attitudes and the therapeutic relationship in different countries.
One hypothesis is that patients in Southern Europe are more
strongly influenced by their doctors to persist with treatment than
patients in Canada or Australia. Such cultural differences have
previously been described between German and Italian popula-
tions [24,25,]. Additionally, standardised prescription protocols for
IMDs exist in Spain, which require frequent patient review [26].
This may lead to stronger doctor-patient interactions and lower
discontinuation rates in Spain.
In contrast to an American and an Italian study reporting an
increased discontinuation rate for patients treated with GA and
IFNb-1b compared to IM IFNb-1a [12,21], our cohort showed a
decrease of discontinuation in patients treated with GA and IFNb-
1b compared to the IFNb-1a products. Our study only includes
one US centre and we did find large differences in product-specific
discontinuation rates between different countries, so it is possible
that these discordant results reflect different study populations.
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The limitations of this study are the same as those that pertain
to other prospective cohort studies, namely that data gathered in
studies such as ours is less complete than that generated by clinical
trials. In order to address this, a central study co-ordinator was
employed to monitor data completeness and follow up with centres
with incomplete records.
At the time of data extraction, detailed (categorical) reasons for
treatment discontinuation were not obtained, however this will be
redressed in the future.
The benefits of IMD treatment in early RRMS and CIS include
reduction in relapse rates, disability progression and MRI activity
[27]. Patients who cease IMD treatment are at greater risk of
relapse activity and disability progression. A better understanding
of the factors influencing higher discontinuation rates in women
and the large geographical differences that we have characterised
in this study could, in the future, allow us to improve management
strategies for patients at high risk of discontinuation.
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